{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:40:05Z","timestamp":1771008005555,"version":"3.50.1"},"reference-count":114,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Iberoamericana de Micolog\u00eda"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.riam.2014.05.001","type":"journal-article","created":{"date-parts":[[2014,6,21]],"date-time":"2014-06-21T17:16:34Z","timestamp":1403370994000},"page":"255-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Farmacolog\u00eda de los antif\u00fangicos en el tratamiento de la aspergilosis"],"prefix":"10.1016","volume":"31","author":[{"given":"Jos\u00e9 Ram\u00f3n","family":"Azanza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"S\u00e1daba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"G\u00f3mez-Gu\u00edu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.riam.2014.05.001_bib0005","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1128\/AAC.00297-07","article-title":"Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents","volume":"51","author":"Abdel-Rahman","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0010","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2165\/00044011-200828070-00002","article-title":"Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: Two prospective, multicentre, open-label, parallel-group volunteer studies","volume":"28","author":"Abel","year":"2008","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.riam.2014.05.001_bib0015","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1128\/AAC.41.10.2201","article-title":"Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): Combined experience from phase i and phase ii studies","volume":"41","author":"Adedoyin","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 5","key":"10.1016\/j.riam.2014.05.001_bib0020","first-page":"S3","article-title":"AmBisome targeting to fungal infections","volume":"14","author":"Adler-Moore","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.riam.2014.05.001_bib0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1179\/joc.2008.20.1.93","article-title":"Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function","volume":"20","author":"Alvarez-Lerma","year":"2008","journal-title":"J Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0030","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/QCO.0b013e328359a56e","article-title":"Making sense of posaconazole therapeutic drug monitoring: A practical approach","volume":"25","author":"Ananda-Rajah","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.riam.2014.05.001_bib0035","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/0091270010365557","article-title":"Increased oral bioavailability of itraconazole and its active metabolite, 7-hydroxyitraconazole, when coadministered with a vitamin C beverage in healthy participants","volume":"51","author":"Bae","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.riam.2014.05.001_bib0040","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/jac\/dki075","article-title":"Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes","volume":"55","author":"Ballesta","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0045","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/AAC.37.4.778","article-title":"Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers","volume":"37","author":"Barone","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1128\/AAC.01540-12","article-title":"Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients","volume":"57","author":"Bartelink","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0055","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1023\/A:1007605024942","article-title":"Safety, toxicokinetics and tissue distribution of long-term intravenous liposomica amphotericin B (AmBisome): A 91-day study in rats","volume":"12","author":"Bekersky","year":"2000","journal-title":"Pharm Res"},{"key":"10.1016\/j.riam.2014.05.001_bib0060","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0065","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1128\/AAC.46.3.834-840.2002","article-title":"Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0070","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijantimicag.2003.05.014","article-title":"Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno-venous haemofiltration","volume":"23","author":"Bellmann","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.riam.2014.05.001_bib0075","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/jac\/dkg139","article-title":"Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration","volume":"51","author":"Bellmann","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0080","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1345\/aph.1R775","article-title":"Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer","volume":"47","author":"Bernardo","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.riam.2014.05.001_bib0085","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1128\/AAC.32.10.1595","article-title":"Itraconazole pharmacokinetics in patients with renal dysfunction","volume":"32","author":"Boelaert","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0090","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1128\/AAC.00700-12","article-title":"Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections","volume":"56","author":"Boyd","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.bmt.1705012","article-title":"Rethinking the use of voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients","volume":"36","author":"Brown","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.riam.2014.05.001_bib0100","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Br\u00fcggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2014.05.001_bib0105","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/FTD.0b013e31817b1a95","article-title":"Therapeutic drug monitoring of voriconazole","volume":"30","author":"Br\u00fcggemann","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.riam.2014.05.001_bib0110","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1128\/AAC.00637-11","article-title":"Concentration of antifungal agents within host cell membranes: A new paradigm governing the efficacy of prophylaxis","volume":"55","author":"Campoli","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0115","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.50.5.1878-1880.2006","article-title":"Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen","volume":"50","author":"Capitano","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0120","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2515\/therapie\/2011015","article-title":"Level of evidence for therapeutic drug monitoring of itraconazole","volume":"66","author":"Charles","year":"2011","journal-title":"Therapie"},{"key":"10.1016\/j.riam.2014.05.001_bib0125","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/FTD.0b013e31823f3516","article-title":"Therapeutic drug monitoring of voriconazole in children","volume":"34","author":"Chen","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.riam.2014.05.001_bib0130","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1128\/AAC.01396-09","article-title":"Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients","volume":"54","author":"Conte","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0135","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1128\/AAC.48.10.3823-3827.2004","article-title":"Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state","volume":"48","author":"Conte","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0140","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","article-title":"Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults","volume":"47","author":"Courtney","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/0091270004271402","article-title":"Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease","volume":"45","author":"Courtney","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.riam.2014.05.001_bib0150","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2125.2003.01977.x","article-title":"Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults","volume":"57","author":"Courtney","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.riam.2014.05.001_bib0155","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1128\/AAC.01042-09","article-title":"Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults","volume":"53","author":"Crandon","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0160","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/422526","article-title":"Pharmacokinetics of voriconazole in the cerebrospinal fluid of an immunocompromised patient with a brain abscess due to Aspergillus fumigatus","volume":"39","author":"Denes","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2014.05.001_bib0165","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/INF.0b013e31824acc33","article-title":"Therapeutic monitoring of voriconazole in children less than three years of age: A case report and summary of voriconazole concentrations for ten children","volume":"31","author":"Doby","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.riam.2014.05.001_bib0170","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1592\/phco.30.8.842","article-title":"Management of drug and food interactions with azole antifungal agents in transplant recipients","volume":"30","author":"Dodds-Ashley","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.riam.2014.05.001_bib0175","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1128\/AAC.00802-12","article-title":"Multicenter study of posaconazole therapeutic drug monitoring: Exposure-response relationship and factors affecting concentration","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0180","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1128\/AAC.05900-11","article-title":"Posaconazole exposure-response relationship: Evaluating the utility of therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0185","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10096-011-1288-9","article-title":"Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: Influence of food intake","volume":"31","author":"Eiden","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.riam.2014.05.001_bib0190","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00003088-200544020-00006","article-title":"Oral bioavailability of posaconazole in fasted healthy subjects: Comparison between three regimens and basis for clinical dosage recommendations","volume":"44","author":"Ezzet","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.riam.2014.05.001_bib0195","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1128\/AAC.01407-09","article-title":"Intracellular concentrations of posaconazole in different compartments of peripheral blood","volume":"54","author":"Farowski","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0200","doi-asserted-by":"crossref","first-page":"2592-2599","DOI":"10.1093\/jac\/dkt229","article-title":"Steady-state pharmacokinetics and metabolism of voriconazole in patients","volume":"68","author":"Geist","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0205","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/14740338.2012.712111","article-title":"Safety and interactions of new antifungals in stem cell transplant recipients","volume":"11","author":"Girmenia","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.riam.2014.05.001_bib0210","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","volume":"52","author":"Goldstein","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.riam.2014.05.001_bib0215","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/315643","article-title":"Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system","volume":"182","author":"Groll","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.riam.2014.05.001_bib0220","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1128\/AAC.00241-06","article-title":"Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations","volume":"50","author":"Groll","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0225","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1439-0507.2009.01820.x","article-title":"Clinically relevant drug interactions of current antifungal agents","volume":"53","author":"Gubbins","year":"2010","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2014.05.001_bib0230","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1517\/17425255.2011.627854","article-title":"Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450","volume":"7","author":"Gubbins","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.riam.2014.05.001_bib0235","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archopht.122.1.42","article-title":"Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans","volume":"122","author":"Hariprasad","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.riam.2014.05.001_bib0240","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/jac\/40.2.295","article-title":"Enhanced pulmonary accumulation of liposomica amphotericin B (AmBisome) in acute liver transplant failure","volume":"40","author":"Heinemann","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0245","first-page":"231","article-title":"Long-term treatment of refractory invasive fungal infection with posaconazole: Additive value of therapeutic drug monitoring","volume":"66","author":"Henckaerts","year":"2011","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.riam.2014.05.001_bib0250","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ijantimicag.2012.02.002","article-title":"Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies","volume":"39","author":"Hoenigl","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.riam.2014.05.001_bib0255","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1128\/AAC.36.2.477","article-title":"Effect of cyclodextrin on the pharmacology of antifungal oral azoles","volume":"36","author":"Hostetler","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0260","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1345\/aph.1L243","article-title":"Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis","volume":"42","author":"Howard","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.riam.2014.05.001_bib0265","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/FTD.0b013e31823cdeac","article-title":"Posaconazole: The case for therapeutic drug monitoring","volume":"34","author":"Howard","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.riam.2014.05.001_bib0270","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1592\/phco.31.2.214","article-title":"Therapeutic drug monitoring of voriconazole and posaconazole","volume":"31","author":"Hussaini","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.riam.2014.05.001_bib0275","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s002280050280","article-title":"Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole","volume":"52","author":"Jaruratanasirikul","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.riam.2014.05.001_bib0280","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-199223040-00004","article-title":"Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics","volume":"23","author":"Janknegt","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.riam.2014.05.001_bib0285","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/AAC.01123-08","article-title":"Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: Major effect on CYPs 2B6, 2C9, 2C19, and 3A","volume":"53","author":"Jeong","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0290","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/jac\/dkg089","article-title":"A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution","volume":"51","author":"Johnson","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0295","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/(SICI)1099-1069(1998030)16:1<33::AID-HON620>3.0.CO;2-9","article-title":"Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: The effect of famotidine on the absorption of itraconazole","volume":"16","author":"Kanda","year":"1998","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.riam.2014.05.001_bib0300","first-page":"255","article-title":"Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene","volume":"63","author":"Kimura","year":"2010","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.riam.2014.05.001_bib0305","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1093\/jac\/dks312","article-title":"Evaluation of the effect of obesity on voriconazole serum concentrations","volume":"67","author":"Koselke","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0310","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1128\/AAC.48.9.3543-3551.2004","article-title":"Disposition of posaconazole following single-dose oral administration in healthy subjects","volume":"48","author":"Krieter","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0315","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1128\/AAC.00889-09","article-title":"Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0320","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1128\/AAC.00454-06","article-title":"Posaconazole plasma concentrations in juvenile patients with invasive fungal infection","volume":"51","author":"Krishna","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0325","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4212\/cjhp.v62i6.845","article-title":"Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections","volume":"62","author":"Kuo","year":"2009","journal-title":"Can J Hosp Pharm"},{"key":"10.1016\/j.riam.2014.05.001_bib0330","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/j.1552-4604.1997.tb04332.x","article-title":"Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers","volume":"37","author":"Lange","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.riam.2014.05.001_bib0335","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1086\/605499","article-title":"Toxicodynamics of itraconazole: Implications for therapeutic drug monitoring","volume":"49","author":"Lestner","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2014.05.001_bib0340","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/10428190701724819","article-title":"Progressive fusariosis: unpredictable bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection","volume":"49","author":"Lewis","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.riam.2014.05.001_bib0345","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2036.1993.tb00103.x","article-title":"Short report: The absorption of fluconazole and itraconazole under conditions of low intragastric acidity","volume":"7","author":"Lim","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.riam.2014.05.001_bib0350","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/ndt\/gfr472","article-title":"Pharmacokinetics of sulfobutylether-\u03b2-cyclodextrin (SBECD) in subjects on hemodialysis","volume":"27","author":"Luke","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.riam.2014.05.001_bib0355","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1086\/377131","article-title":"Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients","volume":"37","author":"Lutsar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2014.05.001_bib0360","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1345\/aph.1Q456","article-title":"Poor absorption of high-dose posaconazole in pediatric bone marrow transplant patients","volume":"46","author":"Matthias","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.riam.2014.05.001_bib0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007990903364657","article-title":"Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment","volume":"26","author":"Moton","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.riam.2014.05.001_bib0370","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children","volume":"50","author":"Neely","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2014.05.001_bib0375","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/cir969","article-title":"Administration of voriconazole in patients with renal dysfunction","volume":"54","author":"Neofytos","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2014.05.001_bib0380","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2165\/0003088-200847120-00003","article-title":"The enzymatic basis of drug-drug interactions with systemic triazole antifungals","volume":"47","author":"Nivoix","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.riam.2014.05.001_bib0385","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/138920009788499012","article-title":"Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care","volume":"10","author":"Nivoix","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.riam.2014.05.001_bib0390","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1248\/yakushi.125.795","article-title":"Drug-drug interaction of antifungal drugs","volume":"125","author":"Niwa","year":"2005","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.riam.2014.05.001_bib0395","doi-asserted-by":"crossref","first-page":"369","DOI":"10.11150\/kansenshogakuzasshi.83.369","article-title":"Influence of black vinegar on itraconazole absorption","volume":"83","author":"Oguma","year":"2009","journal-title":"Kansenshogaku Zasshi"},{"key":"10.1016\/j.riam.2014.05.001_bib0400","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1128\/AAC.01765-10","article-title":"Steady-state plasma pharmacokinetics of oral voriconazole in obese adults","volume":"55","author":"Pai","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0405","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cis437","article-title":"Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: Population pharmacokinetics-based analysis of adult patients with invasive fungal infections","volume":"55","author":"Pascual","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2014.05.001_bib0410","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1053\/j.ajkd.2004.09.017","article-title":"Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients","volume":"45","author":"Peng","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.riam.2014.05.001_bib0415","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1128\/AAC.37.4.903","article-title":"Uptake of itraconazole by alveolar macrophages","volume":"37","author":"Perfect","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.riam.2014.05.001_bib0420","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2125.2003.01993.x","article-title":"Voriconazole, a novel wide-spectrum triazole: Oral pharmacokinetics and safety","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.riam.2014.05.001_bib0425","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1365-2125.2003.01994.x","article-title":"Effect of food on the pharmacokinetics of multiple-dose oral voriconazole","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.riam.2014.05.001_bib0430","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1365-2125.2003.01999.x","article-title":"Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.riam.2014.05.001_bib0435","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/FTD.0b013e3182205d93","article-title":"1st Medical Department, ICU, Charles. Pharmacokinetic evaluation of voriconazole treatment in critically ill patients undergoing continuous venovenous hemofiltration","volume":"33","author":"Radej","year":"2011","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.riam.2014.05.001_bib0440","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/bmt.2009.17","article-title":"Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis","volume":"44","author":"Reinwald","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.riam.2014.05.001_bib0445","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11592900-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid: Focus on antifungal, antitubercular and miscellaneous anti-infective agents","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.riam.2014.05.001_bib0450","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijantimicag.2012.09.001","article-title":"Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis","volume":"40","author":"Ross","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.riam.2014.05.001_bib0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00228-012-1310-x","article-title":"Azole interactions with multidrug therapy in pediatric oncology","volume":"69","author":"Ruggiero","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.riam.2014.05.001_bib0460","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/ACO.0b013e32833a254d","article-title":"Azole antimycotics and drug interactions in the perioperative period","volume":"23","author":"Saari","year":"2010","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.1016\/j.riam.2014.05.001_bib0465","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1128\/AAC.50.5.1881-1883.2006","article-title":"Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers","volume":"50","author":"Sansone-Parsons","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0470","unstructured":"Schwartz S. Fungicidal concentrations of voriconazole in brain abscess and cerebrospinal fluid in a patient with Candida meningoencephalitis. Chicago: 47th ISAAC; 2007 (M-1161."},{"key":"10.1016\/j.riam.2014.05.001_bib0475","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s15010-011-0108-6","article-title":"The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: A retrospective analysis","volume":"39","author":"Schwartz","year":"2011","journal-title":"Infection"},{"key":"10.1016\/j.riam.2014.05.001_bib0480","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1439-0507.2007.01345.x","article-title":"Poor efficacy of amphotericin B-based therapy in CNS aspergillosis","volume":"50","author":"Schwartz","year":"2007","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2014.05.001_bib0485","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/FTD.0b013e318167d0e0","article-title":"Therapeutic drug monitoring of antifungals: Pharmacokinetic and pharmacodynamic considerations","volume":"30","author":"Smith","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.riam.2014.05.001_bib0490","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/FTD.0b013e31827d76b0","article-title":"Pharmacokinetic profile of voriconazole in a critically ill patient on therapeutic plasma exchange","volume":"35","author":"Spriet","year":"2013","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.riam.2014.05.001_bib0495","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10096-010-1079-8","article-title":"Voriconazole plasma levels in children are highly variable","volume":"30","author":"Spriet","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.riam.2014.05.001_bib0500","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1469-0691.2004.00981.x","article-title":"Successful treatment of brain aspergillosis with voriconazole","volume":"10","author":"Tattevin","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2014.05.001_bib0505","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.clpt.6100230","article-title":"Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo","volume":"83","author":"Templeton","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.riam.2014.05.001_bib0510","unstructured":"U.S. Food and Drug Administration, Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [consultado 18 Jun 2014]. Disponible en: http:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/developmentresources\/druginteractionslabeling\/ucm093664.htm"},{"key":"10.1016\/j.riam.2014.05.001_bib0515","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1128\/AAC.01177-12","article-title":"Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome","volume":"56","author":"Vaes","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2014.05.001_bib0520","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/j.1875-9114.1996.tb02973.x","article-title":"Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole","volume":"16","author":"Van de Velde","year":"1996","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.riam.2014.05.001_bib0525","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00228-012-1212-y","article-title":"Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome","volume":"68","author":"Vehreschild","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.riam.2014.05.001_bib0530","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","article-title":"Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance","volume":"38","author":"Venkatakrishnan","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.riam.2014.05.001_bib0535","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1525-1594.2006.00192.x","article-title":"Pharmacokinetics of liposomal amphotericin B during extracorporeal albumin dialysis","volume":"30","author":"Vogelsinger","year":"2006","journal-title":"Artif Organs"},{"key":"10.1016\/j.riam.2014.05.001_bib0540","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1128\/AAC.00896-10","article-title":"Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children","volume":"54","author":"Walsh","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2014.05.001_bib0545","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3109\/10611869408996812","article-title":"The interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu","volume":"2","author":"Wasan","year":"1994","journal-title":"J Drug Target"},{"issue":"Suppl 3","key":"10.1016\/j.riam.2014.05.001_bib0550","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/j.ijid.2009.07.020","article-title":"Comparison between concentrations of amphotericin B in infected lung lesion and in uninfected lung tissue in a patient treated with liposomica amphotericin B (AmBisome)","volume":"14","author":"Watanabe","year":"2010","journal-title":"Int J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.riam.2014.05.001_bib0555","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1046\/j.1365-2125.2003.02000.x","article-title":"Effect of omeprazole on the steady-state pharmacokinetics of voriconazole","volume":"56","author":"Wood","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.riam.2014.05.001_bib0560","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1124\/dmd.107.019646","article-title":"Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes","volume":"36","author":"Yanni","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.riam.2014.05.001_bib0565","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1124\/dmd.109.029769","article-title":"In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: Role of CYP2C19 and flavin-containing monooxygenase 3","volume":"38","author":"Yanni","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.riam.2014.05.001_bib0570","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/j.1552-4604.1998.tb04465.x","article-title":"A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection","volume":"38","author":"Zhou","year":"1998","journal-title":"J Clin Pharmacol"}],"container-title":["Revista Iberoamericana de Micolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140614000448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140614000448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T12:28:06Z","timestamp":1746275286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130140614000448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":114,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1130140614000448"],"URL":"https:\/\/doi.org\/10.1016\/j.riam.2014.05.001","relation":{},"ISSN":["1130-1406"],"issn-type":[{"value":"1130-1406","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Farmacolog\u00eda de los antif\u00fangicos en el tratamiento de la aspergilosis","name":"articletitle","label":"Article Title"},{"value":"Revista Iberoamericana de Micolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.riam.2014.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Espa\u00f1a, S.L.","name":"copyright","label":"Copyright"}]}}